BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32058557)

  • 21. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
    Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study.
    Mary F; Zaanan A; Boige V; Artru P; Samalin E; Coriat R; Bachet JB; Boubaya M; Benallaoua M; Tougeron D; Afchain P; Locher C; Baumgaertner I; Lecaille C; des Guetz G; Aparicio T;
    Dig Liver Dis; 2016 Dec; 48(12):1498-1502. PubMed ID: 27623185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
    Mukherjee S; Fountzilas C; Boland PM; Gosain R; Attwood K; Tan W; Khushalani N; Iyer R
    Target Oncol; 2020 Feb; 15(1):85-92. PubMed ID: 31802410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial.
    Lin JX; Xu YC; Lin W; Xue FQ; Ye JX; Zang WD; Cai LS; You J; Xu JH; Cai JC; Tang YH; Xie JW; Li P; Zheng CH; Huang CM
    JAMA Netw Open; 2021 Jul; 4(7):e2116240. PubMed ID: 34241629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
    Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
    Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
    Stathopoulos GP; Rigatos SK; Stathopoulos JG; Xynotroulas JP; Dimou E
    Am J Clin Oncol; 2005 Dec; 28(6):565-9. PubMed ID: 16317265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
    Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
    Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study.
    Newman E; Potmesil M; Ryan T; Marcus S; Hiotis S; Yee H; Norwood B; Wendell M; Muggia F; Hochster H
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S97-100. PubMed ID: 16399443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.
    Rosenberg AJ; Rademaker A; Hochster HS; Ryan T; Hensing T; Shankaran V; Baddi L; Mahalingam D; Mulcahy MF; Benson AB
    Oncologist; 2019 Aug; 24(8):1039-e642. PubMed ID: 31138725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial.
    Zheng Y; Yang X; Yan C; Feng R; Sah BK; Yang Z; Zhu Z; Liu W; Xu W; Ni Z; Beeharry MK; Hua Z; Yan M; Zhu Z; Li C
    Eur J Cancer; 2020 May; 130():12-19. PubMed ID: 32171104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
    JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
    Glynne-Jones R; Falk S; Maughan TS; Meadows HM; Sebag-Montefiore D
    Br J Cancer; 2007 Feb; 96(4):551-8. PubMed ID: 17262086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by
    Zhu J; Liu A; Sun X; Liu L; Zhu Y; Zhang T; Jia J; Tan S; Wu J; Wang X; Zhou J; Yang J; Zhang C; Zhang H; Zhao Y; Cai G; Zhang W; Xia F; Wan J; Zhang H; Shen L; Cai S; Zhang Z
    J Clin Oncol; 2020 Dec; 38(36):4231-4239. PubMed ID: 33119477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction.
    Zhao Q; Li Y; Wang J; Zhang J; Qiao X; Tan B; Tian Y; Shi G; Xu Q; Li R; Liu Y; Yang P
    Am J Med Sci; 2015 Jun; 349(6):472-6. PubMed ID: 25996101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
    Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
    Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer.
    Movsas B; Hanlon AL; Lanciano R; Scher RM; Weiner LM; Sigurdson ER; Hoffman JP; Eisenberg BL; Cooper HS; Provins S; Coia LR
    Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):43-50. PubMed ID: 9747818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
    Goel G; Jauhri M; Negi A; Aggarwal S
    Hematol Oncol Stem Cell Ther; 2010; 3(2):55-9. PubMed ID: 20543537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
    Lee J; Kang WK; Kwon JM; Oh SY; Lee HR; Kim HJ; Park BB; Lim HY; Han MJ; Park JO; Park YS
    Ann Oncol; 2007 Jan; 18(1):88-92. PubMed ID: 16971670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study.
    Pozzo C; Barone C; Szanto J; Padi E; Peschel C; Bükki J; Gorbunova V; Valvere V; Zaluski J; Biakhov M; Zuber E; Jacques C; Bugat R
    Ann Oncol; 2004 Dec; 15(12):1773-81. PubMed ID: 15550582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.